• MetaVia Inc. (MTVA) shares are up 5.1% today, trading at $1.64.
  • The company announced successful completion of dose titration for all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, its obesity drug candidate.
  • Topline data from the Phase 1 trial remains on track to be released in the fourth quarter of 2026.